Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Articles by Barry C. Lubin
Total Records ( 2 ) for Barry C. Lubin
  Kevin Carl Maki , Mary R. Dicklin , Barry C. Lubin , James M. McKenney and Matthew S. Reeves
  not available
  Kevin C. Maki , Barry C. Lubin , Matthew S. Reeves , Mary R. Dicklin and William S. Harris


Prescription omega-3 acid ethyl esters (P-OM3) plus simvastatin 20 and 40 mg/day improves lipids in subjects with mixed dyslipidemia, but no previous studies have examined P-OM3 with the maximum prescribed dose of simvastatin (80 mg).


To assess the effects of P-OM3 + simvastatin 80 mg versus P-OM3 + simvastatin 20 mg or placebo + simvastatin 20 mg on non-high-density lipoprotein cholesterol (non-HDL-C) and other lipid concentrations.


Subjects with mixed dyslipidemia who had completed a 12-week double-blind crossover study of simvastatin 20 mg/day + either placebo or P-OM3 4 g/day were enrolled. An analysis (n = 14) was performed following the first six weeks of the extension, during which all subjects received open-label P-OM3 + open-label simvastatin 80 mg/day.


P-OM3 + simvastatin 80 mg resulted in significantly larger reductions from baseline (P < .05 for all) versus P-OM3 + simvastatin 20 mg and placebo + simvastatin 20 mg, respectively, for non-HDL-C (−51.0%, −40.8%, −34.9%), low-density lipoprotein cholesterol (−48.0%, −35.5%, −38.0%), total cholesterol (TC) (−42.6%, −31.9%, −27.1%), the TC/HDL-C ratio (−52.9%, −44.3%, −36.2%), and apolipoprotein B (−42.6%, −32.6%, −30.5%). P-OM3 + simvastatin (80- and 20-mg doses, respectively) resulted in significantly larger changes from baseline (P < .05 for all) versus placebo in very low-density lipoprotein cholesterol (−50.7%, −47.9%, −23.0%), triglycerides (TG; −58.6%, −54.7%, −32.0%), HDL-C (24.5%, 20.7%, 17.9%), and the TG/HDL-C ratio (−66.5%, −62.3%, −42.5%).


These results suggest non-HDL-C, TG (both 50% to 60%), and HDL-C (∼25%) concentrations can be markedly improved by a combination of P-OM3 (4 g/day) and simvastatin (80 mg/day) in subjects with mixed dyslipidemia.

Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility